Interleukin 2 (IL-2) (IL-2)

Interleukin 2 (IL-2) is a critical type I cytokine and signaling molecule that regulates the activities of white blood cells, particularly T lymphocytes and natural killer cells, by promoting their expansion and maturation [1]. It is encoded by the IL2 gene, and the specific term 'IL-2 gene expression' refers to the transcriptional process that is a major checkpoint in immune activation [2]. In clinical practice, suppressing IL-2 gene expression is a key strategy for preventing organ transplant rejection; drugs like cyclosporine and tacrolimus achieve this by inhibiting calcineurin, thereby preventing the transcription factors necessary for IL-2 production [3]. Conversely, recombinant versions of the IL-2 protein, such as aldesleukin, are used in oncology to boost the immune system's ability to fight metastatic melanoma and renal cell carcinoma [4]. However, IL-2 signaling is biologically complex because it also supports regulatory T-cells (Tregs) that maintain self-tolerance, and its therapeutic use is often limited by severe systemic toxicities like capillary leak syndrome [1, 5]. Consequently, the phrase 'IL-2 gene expression' is typically used as a pharmacological endpoint or a marker of T-cell activation rather than a standalone molecule [2, 3].

Other names

IL2Interleukin-2T-cell growth factorTCGFAldesleukinLymphokine

Drugs targeting this pathway act by either inhibiting IL-2 gene transcription via calcineurin/NFAT pathway blockade, agonizing the IL-2 receptor complex to stimulate immune effector cells, or antagonizing the IL-2 receptor alpha chain (CD25) to prevent T-cell activation.